Andreas Krause

Title: The Innovative Contributions of Andreas Krause

Introduction

Andreas Krause is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, holding a total of seven patents. His work focuses on innovative compounds and dosing regimens that have the potential to impact therapeutic practices.

Latest Patents

One of his latest patents is titled "Dosing regimen for a selective S1P1 receptor agonist." This invention relates to a specific dosing regimen for the compound (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimmo)-3-o-tolyl-thiazolidin-4-one. Another significant patent is for a "Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol," which pertains to a crystalline form of the compound that has potential applications in various therapeutic areas.

Career Highlights

Throughout his career, Andreas Krause has worked with prominent companies in the pharmaceutical industry. He has been associated with Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd, where he has contributed to the development of innovative therapeutic solutions. His expertise in the field has allowed him to make substantial advancements in drug formulation and delivery.

Collaborations

Andreas has collaborated with notable professionals in the industry, including Jasper Dingemanse and Matthias Hoch. These collaborations have further enhanced his research and development efforts, leading to the successful creation of new pharmaceutical compounds.

Conclusion

Andreas Krause's contributions to the field of pharmaceuticals through his patents and collaborations highlight his innovative spirit and dedication to advancing medical science. His work continues to influence the development of new therapies that can improve patient outcomes.